Higher IL-6 signaling promotes insulin resistance and endothelial dysfunction.

Interleukin-6 (IL-6) acts as a critical pleiotropic cytokine that modulates both metabolic and vascular health. Its role in insulin resistance and endothelial dysfunction is well-established through specific molecular pathways that antagonize insulin action and impair nitric oxide synthesis.

Clinical and mechanistic evidence

IL-6 signaling is a primary driver of systemic insulin resistance and vascular impairment.

• Insulin resistance mechanisms: Chronic IL-6 exposure induces SOCS3 (suppressor of cytokine signaling 3), which directly inhibits the phosphorylation of insulin receptor substrate-1 (IRS-1). This blocks the PI3K/Akt pathway, preventing GLUT4 translocation and effectively reducing glucose uptake in muscle and adipose tissue.
• Endothelial dysfunction: IL-6 disrupts the eNOS (endothelial nitric oxide synthase) pathway by interfering with insulin-stimulated IRS-1/PI3K/Akt signaling within endothelial cells. This leads to diminished nitric oxide production, a key factor in impaired vasodilation and the development of atherosclerosis.
• Causal links: Mendelian randomization studies and clinical trials using IL-6 inhibitors (e.g., tocilizumab) support a causal relationship between IL-6 signaling and vascular disease. In clinical settings, IL-6 inhibition has been shown to improve flow-mediated dilation (FMD), a standard measure of endothelial health.

Genetic variation and population effects

The IL-6 rs1800795 (-174 G/C) polymorphism influences IL-6 transcription, though its effect is highly dependent on ethnic background and physiological context.

• Expression patterns: While the G allele is frequently linked to higher transcriptional activity in European populations, the CC genotype is associated with higher serum IL-6 levels and a more pro-inflammatory profile in other groups, such as South Indian cohorts.
• Population frequency: The prevalence of the C allele varies significantly; it is common in European populations but nearly absent in East Asian populations, which dictates how this genetic variant influences disease risk across different demographics.

Bottom line

Higher IL-6 signaling is a confirmed promoter of insulin resistance and endothelial dysfunction via SOCS3 and eNOS inhibition. The rs1800795 CC genotype is a plausible driver of higher IL-6 expression in specific populations, although its metabolic impact remains context-dependent.